{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:59:19Z","timestamp":1780984759103,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH 23FC1019"],"award-info":[{"award-number":["JPMH 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15358"],"award-info":[{"award-number":["23K15358"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010391","name":"Tokyo Women's Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08139-2","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:15:02Z","timestamp":1777414502000},"page":"3235-3245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increasing proportion and more favourable outcomes of seronegative rheumatoid arthritis: analysis of the IORRA cohort from 2000 to 2021"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-2560","authenticated-orcid":false,"given":"Tomoaki","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-326X","authenticated-orcid":false,"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-7769","authenticated-orcid":false,"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-2005","authenticated-orcid":false,"given":"Katsunori","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"8139_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090743","volume":"13","author":"J Perera","year":"2024","unstructured":"Perera J, Delrosso CA, Nerviani A, Pitzalis C (2024) Clinical phenotypes, serological biomarkers, and synovial features defining seropositive and seronegative rheumatoid arthritis: a literature review. Cells 13:743. https:\/\/doi.org\/10.3390\/cells13090743","journal-title":"Cells"},{"key":"8139_CR2","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"8139_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00281-017-0627-z","volume":"39","author":"VF Derksen","year":"2017","unstructured":"Derksen VF, Huizinga TW, Van Der Woude D (2017) The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol 39:437\u2013446","journal-title":"Semin Immunopathol"},{"key":"8139_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00242-4","volume":"5","author":"S Bugatti","year":"2023","unstructured":"Bugatti S, De Stefano L, Gandolfo S et al (2023) Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist. Lancet Rheumatol 5:e743. https:\/\/doi.org\/10.1016\/S2665-9913(23)00242-4","journal-title":"Lancet Rheumatol"},{"key":"8139_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3899\/jrheum.160670","volume":"44","author":"MLT Berendsen","year":"2017","unstructured":"Berendsen MLT, van Maaren MC, Arts EEA et al (2017) Anticyclic citrullinated peptide antibodies and rheumatoid factor as risk factors for 10-year cardiovascular morbidity in patients with rheumatoid arthritis: a large inception cohort study. J Rheumatol 44:1325\u20131330. https:\/\/doi.org\/10.3899\/jrheum.160670","journal-title":"J Rheumatol"},{"key":"8139_CR6","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","volume":"53","author":"CA Kelly","year":"2014","unstructured":"Kelly CA, Saravanan V, Nisar M et al (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2013a large multicentre UK study. Rheumatology (Oxford) 53:1676\u20131682. https:\/\/doi.org\/10.1093\/rheumatology\/keu165","journal-title":"Rheumatology (Oxford)"},{"key":"8139_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105800","volume":"92","author":"S Bugatti","year":"2025","unstructured":"Bugatti S, Montecucco C (2025) Seronegative rheumatoid arthritis: neglected in clinical trials, a giant in clinical practice. Joint Bone Spine 92:105800. https:\/\/doi.org\/10.1016\/j.jbspin.2024.105800","journal-title":"Joint Bone Spine"},{"key":"8139_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","volume":"40","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Jain A, Askling J et al (2010) A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 40:2-14.e1. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.03.003","journal-title":"Semin Arthritis Rheum"},{"key":"8139_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","volume":"60","author":"DS Courvoisier","year":"2021","unstructured":"Courvoisier DS, Chatzidionysiou K, Mongin D et al (2021) The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford) 60:820\u2013828. https:\/\/doi.org\/10.1093\/rheumatology\/keaa393","journal-title":"Rheumatology (Oxford)"},{"key":"8139_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","volume":"79","author":"E Myasoedova","year":"2020","unstructured":"Myasoedova E, Davis J, Matteson EL, Crowson CS (2020) Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985\u20132014. Ann Rheum Dis 79:440\u2013444. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216694","journal-title":"Ann Rheum Dis"},{"key":"8139_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3899\/jrheum.2024-0560","volume":"52","author":"N Carrier","year":"2025","unstructured":"Carrier N, Roux S, Masetto A et al (2025) Changes at Presentation in Patients With Early Rheumatoid Arthritis: A 24-Year Study of the Early Undifferentiated Polyarthritis (EUPA) Cohort. J Rheumatol 52:119\u2013127. https:\/\/doi.org\/10.3899\/jrheum.2024-0560","journal-title":"J Rheumatol"},{"key":"8139_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00296-022-05268-0","volume":"43","author":"P Elfving","year":"2023","unstructured":"Elfving P, Kononoff A, Huhtakangas J et al (2023) Incidence of seropositive rheumatoid arthritis in population-based studies in Northern Savo, Finland, during 1980-2020. Rheumatol Int 43:659\u2013666. https:\/\/doi.org\/10.1007\/s00296-022-05268-0","journal-title":"Rheumatol Int"},{"key":"8139_CR13","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/art.10360","volume":"46","author":"I Enzer","year":"2002","unstructured":"Enzer I, Dunn G, Jacobsson L et al (2002) An epidemiologic study of trends in prevalence of rheumatoid factor seropositivity in Pima Indians: evidence of a decline due to both secular and birth-cohort influences. Arthritis Rheum 46:1729\u20131734. https:\/\/doi.org\/10.1002\/art.10360","journal-title":"Arthritis Rheum"},{"key":"8139_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10654-018-0360-5","volume":"33","author":"AK Hedstr\u00f6m","year":"2018","unstructured":"Hedstr\u00f6m AK, Stawiarz L, Klareskog L, Alfredsson L (2018) Smoking and susceptibility to rheumatoid arthritis in a Swedish population-based case-control study. Eur J Epidemiol 33:415\u2013423. https:\/\/doi.org\/10.1007\/s10654-018-0360-5","journal-title":"Eur J Epidemiol"},{"key":"8139_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/acr.21660","volume":"65","author":"CS Crowson","year":"2013","unstructured":"Crowson CS, Matteson EL, Davis JM, Gabriel SE (2013) Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken) 65:71\u201377. https:\/\/doi.org\/10.1002\/acr.21660","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8139_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195550","volume":"13","author":"S Choi","year":"2018","unstructured":"Choi S, Lee K-H (2018) Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study. PLoS ONE 13:e0195550. https:\/\/doi.org\/10.1371\/journal.pone.0195550","journal-title":"PLoS ONE"},{"key":"8139_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000752","volume":"4","author":"LB Nordberg","year":"2018","unstructured":"Nordberg LB, Lillegraven S, Aga A-B et al (2018) Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR\/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open 4:e000752. https:\/\/doi.org\/10.1136\/rmdopen-2018-000752","journal-title":"RMD Open"},{"key":"8139_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Tanaka E, Nakajima A et al (2020) A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today\u2019s treatment options. Mod Rheumatol 30:1\u20136. https:\/\/doi.org\/10.1080\/14397595.2019.1660028","journal-title":"Mod Rheumatol"},{"key":"8139_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324. https:\/\/doi.org\/10.1002\/art.1780310302","journal-title":"Arthritis Rheum"},{"key":"8139_CR20","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/ard.2004.033571","volume":"64","author":"J Ronnelid","year":"2005","unstructured":"Ronnelid J, Wick M, Lampa J et al (2005) Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744\u20131749. https:\/\/doi.org\/10.1136\/ard.2004.033571","journal-title":"Ann Rheum Dis"},{"key":"8139_CR21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.55563\/clinexprheumatol\/1h6h71","volume":"41","author":"S Hilliquin","year":"2023","unstructured":"Hilliquin S, Herrou J, Gutermann L et al (2023) Changes of anti-citrullinated peptide antibodies titers after biologic treatment in patients with rheumatoid arthritis: a systematic literature review and retrospective study. Clin Exp Rheumatol 41:1417\u20131426. https:\/\/doi.org\/10.55563\/clinexprheumatol\/1h6h71","journal-title":"Clin Exp Rheumatol"},{"key":"8139_CR22","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","volume":"43","author":"J Fransen","year":"2004","unstructured":"Fransen J, Creemers MCW, Van Riel PLCM (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43:1252\u20131255. https:\/\/doi.org\/10.1093\/rheumatology\/keh297","journal-title":"Rheumatology (Oxford)"},{"key":"8139_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G et al (2011) American college of rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413. https:\/\/doi.org\/10.1136\/ard.2011.149765","journal-title":"Ann Rheum Dis"},{"key":"8139_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.42347","volume":"75","author":"P Studenic","year":"2023","unstructured":"Studenic P, Aletaha D, de Wit M et al (2023) American college of rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol 75:15\u201322. https:\/\/doi.org\/10.1002\/art.42347","journal-title":"Arthritis Rheumatol"},{"key":"8139_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217609","volume":"81","author":"XME Matthijssen","year":"2022","unstructured":"Matthijssen XME, Huizinga TWJ, van der Helm-van Mil AHM (2022) Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population. Ann Rheum Dis 81:e69. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217609","journal-title":"Ann Rheum Dis"},{"key":"8139_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/03009742.2024.2365540","volume":"53","author":"BG Soussi","year":"2024","unstructured":"Soussi BG, Cordtz RL, Duch K et al (2024) Incidence of seropositive and seronegative rheumatoid arthritis in Denmark: a nationwide population-based study. Scand J Rheumatol 53:316\u2013324. https:\/\/doi.org\/10.1080\/03009742.2024.2365540","journal-title":"Scand J Rheumatol"},{"key":"8139_CR27","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1093\/rheumatology\/keaa623","volume":"60","author":"K Paalanen","year":"2021","unstructured":"Paalanen K, Puolakka K, Nikiphorou E et al (2021) Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study. Rheumatology (Oxford) 60:2391\u20132395. https:\/\/doi.org\/10.1093\/rheumatology\/keaa623","journal-title":"Rheumatology (Oxford)"},{"key":"8139_CR28","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/mr\/roab096","volume":"32","author":"Y Matsubara","year":"2022","unstructured":"Matsubara Y, Nakamura Y, Tamura N et al (2022) A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan. Mod Rheumatol 32:960\u2013967. https:\/\/doi.org\/10.1093\/mr\/roab096","journal-title":"Mod Rheumatol"},{"key":"8139_CR29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/ard.2005.041079","volume":"65","author":"SP Linn-Rasker","year":"2006","unstructured":"Linn-Rasker SP, van der Helm-van Mil AHM, van Gaalen FA et al (2006) Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65:366\u2013371. https:\/\/doi.org\/10.1136\/ard.2005.041079","journal-title":"Ann Rheum Dis"},{"key":"8139_CR30","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1136\/annrheumdis-2019-215463","volume":"78","author":"Y Ishikawa","year":"2019","unstructured":"Ishikawa Y, Ikari K, Hashimoto M et al (2019) Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor. Ann Rheum Dis 78:1480\u20131487. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215463","journal-title":"Ann Rheum Dis"},{"key":"8139_CR31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3899\/jrheum.220526","volume":"50","author":"S Takanashi","year":"2023","unstructured":"Takanashi S, Takeuchi T, Kaneko Y (2023) Effects of aging on rheumatoid factor and anticyclic citrullinated peptide antibody positivity in patients with rheumatoid arthritis. J Rheumatol 50:330\u2013334. https:\/\/doi.org\/10.3899\/jrheum.220526","journal-title":"J Rheumatol"},{"key":"8139_CR32","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1093\/rheumatology\/keaf045","volume":"64","author":"A Gupta","year":"2025","unstructured":"Gupta A, Anis S, de Pablo P (2025) Imaging tests as predictors of progression to rheumatoid arthritis in clinically suspect arthralgia: a systematic review and meta-analysis. Rheumatology (Oxford) 64:3255\u20133265. https:\/\/doi.org\/10.1093\/rheumatology\/keaf045","journal-title":"Rheumatology (Oxford)"},{"key":"8139_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3109\/14397595.2015.1069457","volume":"26","author":"K Minowa","year":"2016","unstructured":"Minowa K, Ogasawara M, Murayama G et al (2016) Predictive grade of ultrasound synovitis for diagnosing rheumatoid arthritis in clinical practice and the possible difference between patients with and without seropositivity. Mod Rheumatol 26:188\u2013193. https:\/\/doi.org\/10.3109\/14397595.2015.1069457","journal-title":"Mod Rheumatol"},{"key":"8139_CR34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1136\/ard.54.6.461","volume":"54","author":"G Stucki","year":"1995","unstructured":"Stucki G, Stucki S, Br\u00fchlmann P, Michel BA (1995) Ceiling effects of the health assessment questionnaire and its modified version in some ambulatory rheumatoid arthritis patients. Ann Rheum Dis 54:461\u2013465. https:\/\/doi.org\/10.1136\/ard.54.6.461","journal-title":"Ann Rheum Dis"},{"key":"8139_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/acr2.11051","volume":"1","author":"JS Andrews","year":"2019","unstructured":"Andrews JS, Trupin L, Wysham KD et al (2019) The impact of frailty on changes in physical function and disease activity among adults with rheumatoid arthritis. ACR Open Rheumatol 1:366\u2013372. https:\/\/doi.org\/10.1002\/acr2.11051","journal-title":"ACR Open Rheumatol"},{"key":"8139_CR36","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/ard.2009.118430","volume":"69","author":"H Radner","year":"2010","unstructured":"Radner H, Smolen JS, Aletaha D (2010) Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 69:536\u2013541. https:\/\/doi.org\/10.1136\/ard.2009.118430","journal-title":"Ann Rheum Dis"},{"key":"8139_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61523-3","volume":"14","author":"FA Khadour","year":"2024","unstructured":"Khadour FA, Khadour YA, Ebrahem BM (2024) A qualitative survey on factors affecting depression and anxiety in patients with rheumatoid arthritis: a cross-sectional study in Syria. Sci Rep 14:11513. https:\/\/doi.org\/10.1038\/s41598-024-61523-3","journal-title":"Sci Rep"},{"key":"8139_CR38","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/acr.23497","volume":"70","author":"AC Boer","year":"2018","unstructured":"Boer AC, Boonen A, van der Helm van Mil AH (2018) Is Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis Still a More Severe Disease Than Anti-Citrullinated Protein Antibody-Negative Rheumatoid Arthritis? A Longitudinal Cohort Study in Rheumatoid Arthritis Patients Diagnosed From 2000 Onward. Arthritis Care Res (Hoboken) 70:987\u2013996. https:\/\/doi.org\/10.1002\/acr.23497","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8139_CR39","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1093\/rheumatology\/keaa845","volume":"60","author":"N Luurssen-Masurel","year":"2021","unstructured":"Luurssen-Masurel N, Weel AEAM, Hazes JMW et al (2021) The impact of different (rheumatoid) arthritis phenotypes on patients\u2019 lives. Rheumatology (Oxford) 60:3716\u20133726. https:\/\/doi.org\/10.1093\/rheumatology\/keaa845","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08139-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08139-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08139-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:24:57Z","timestamp":1780982697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08139-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8139"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08139-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The IORRA cohort study was approved by the Ethics Committee of Tokyo Women\u2019s Medical University (approval no. 2952-R2 and 2922-R16) and performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent:"}},{"value":"Tomoaki Higuchi received lecture fees from Asahi Kasei Corp.; Astellas Pharma Inc.; AstraZeneca K.K.; Boehringer Ingelheim Japan, Inc.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Eli Lilly Japan K.K.; Gilead Sciences Inc.; Janssen Pharmaceutical K.K.; Kissei Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Taisho Pharmaceutical Co., Ltd.; UCB Japan Co., Ltd., and collaborative research fund from H.U. Group Research Institute G.K. Eiichi Tanaka received lecture or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kyowa Pharma Chemical Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Eisuke Inoue received lecture or consulting fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd. Katsunori Ikari received speaker fees from Asahi Kasei Corp., Astellas Pharma Inc., AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd., and UCB Japan Co. Ltd. Masayoshi Harigai received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekisui Medical, Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. In addition, Masayoshi Harigai received speaker fees from AbbVie Japan GK, AstraZeneca K.K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Japan, Pfizer Japan Inc., CIMIC Holdings Co., Ltd., Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd., and UCB Japan Co. Ltd. Masayoshi Harigai is a consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}